MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ
28.86
+1.10
+3.96%
After Hours: 27.83 -1.03 -3.58% 19:43 02/06 EST
OPEN
28.25
PREV CLOSE
27.76
HIGH
28.95
LOW
27.83
VOLUME
1.62M
TURNOVER
--
52 WEEK HIGH
46.48
52 WEEK LOW
25.28
MARKET CAP
4.58B
P/E (TTM)
10.39
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina
Reuters · 22h ago
BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Biogen, Bloom Energy, Ubiquiti
Reuters · 1d ago
BUZZ-TG Therapeutics rises on new data for autoimmune therapy
Reuters · 1d ago
TG Therapeutics startet Phase-3-Studie zu Ublituximab bei Kindern und Jugendlichen mit Multipler Sklerose
Reuters · 1d ago
TG Therapeutics Unveils New BRIUMVI Data for Multiple Sclerosis at ACTRIMS Forum
Reuters · 1d ago
TG THERAPEUTICS ANNOUNCES PRESENTATION OF DATA FOR BRIUMVI® (UBLITUXIMAB) IN MULTIPLE SCLEROSIS AT THE AMERICAS COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS ANNUAL FORUM
Reuters · 1d ago
TG Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 4d ago
More
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

Webull offers TG Therapeutics Inc stock information, including NASDAQ: TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.